Matsuba R, et al. - Using the hyperinsulinaemic-euglycaemic clamp method, authors inspected the impact of tofogliflozin, a sodium-glucose co-transporter-2 inhibitor, on peripheral glucose uptake in patients with type 2 diabetes mellitus (T2DM). Findings illustrated a marked decrease in glycated haemoglobin, body weight (BW), body fat mass and lean body mass after 12 weeks. A substantial improvement was noted in the insulin sensitivity and peripheral glucose uptake due to tofogliflozin in subjects with T2DM. Such improvements appeared to be prominently related to a reduction in body fat mass.